Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1144 - Outcomes and prognostic factors in re-irradiation of intracranial gliomas :Single institution experience. (129P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Surgical Oncology;  Radiation Oncology;  Central Nervous System Malignancies

Presenters

Sayan Paul

Citation

Annals of Oncology (2017) 28 (suppl_10): x35-x38. 10.1093/annonc/mdx657

Authors

S. Paul1, N. Sesikeran1, V.P. Reddy1, K. Bhattacharyya1, S.T. Ahmed1, R. Patlola2, P. Upadhyay1, V.K. Reddy1, K. Mohanti1, S. Reddy1

Author affiliations

  • 1 Radiation Oncology, Apollo Cancer Institute, 500096 - Hyderabad/IN
  • 2 Science And Engineering, Princeton University, 08544 - Princeton/US
More

Resources

Abstract 1144

Background

The treatment options for recurrent gliomas are limited. Re-irradiation is being increasingly considered as an option, in view of the advances in treatment techniques, the ability to document doses and overlay plans. However, there is lack of data on outcomes, cumulative doses and prognostic factors in re-irradiation of gliomas. This study attempts to collate a single institutions’ data on re-irradiation of gliomas.

Methods

This is a retrospective analysis of outcomes and prognostic factors in re-irradiation of intracranial gliomas. All patients of gliomas who received re-irradiation between January 2012 to January 2017 were included. Medical records were evaluated to collect data on outcomes of 22 patients treated in a single institution. Survival curve was estimated using Kaplan maier method. Pearsons correlation co-efficient was used to identify factors correlating with better survival.

Results

Median age of patients undergoing re-irradiation was 45yrs (8-66yrs), of which 59% were female, 41% male. The histopathological diagnosis at initial radiation was predominantly grade2 (50%) and grade 3 (31.8%), only 18.1% were glioblastomas. However, at the time of re-irradiation, most common diagnosis was grade 3 glioma (40.9%). Glioblastomas were 36.3%, grade 2 gliomas were 18.1% and 4.5% did not undergo biopsy or surgery at recurrence. Median cumulative dose in 2Gy equivalent – NTD (Normalized Total Dose) was 108Gy (94Gy – 120Gy). Re-irradiation was delivered at standard fractionation in all except one patient, who received hypofractionated dose of 3.5Gy per fraction. Median time interval between the two courses of radiation was 38 months (12-360 months). All patients received IMRT, image guidance. Median re-irradiation volume was 405cc. ROC curve was generated, which showed thatcummulative dose of 115Gy and above was associated with better survival. There were no reported cases of symptomatic brainnecrosis. Median survival was 24 months following re-irradiation. Among the various prognostic factors tested, tumor volume at the time of re-irradiation was the only factor which correlated with survival.

Conclusions

Re-irradiation of gliomas should be considered a valid option in select cases, particularly in small volume recurrences. IMRT with image guidance with conventional fractionation upto total cumulative dose of 115Gy can be considered safe.

Clinical trial identification

Legal entity responsible for the study

Department of Radiation Oncology, Apollo Cancer Institute, Hyderabad

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.